文献速递肾癌与肾肿瘤

TOP2A、HELLS、ATAD2与TET3是肾细胞癌的新型预后标志物

TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma.
PubMed 文献 · Urology · 2017-01-06

研究从正常肾组织、原发G1和G3肿瘤(各14例)及32例转移灶中分离RNA,用寡核苷酸微阵列筛选在肿瘤进展中表达升高的基因,并在55例原发肿瘤独立队列中用定量实时聚合酶链反应验证。TOP2A(HR=4.3,P=.005)、HELLS(HR=3.7,P=.007)、ATAD2(HR=3.7,P=.019)和TET3(HR=2.8,P=.035)的高mRNA水平是肾细胞癌癌症特异性生存的独立预测因子。

要点

  • TOP2A、HELLS、ATAD2、TET3高mRNA水平是肾细胞癌不良结局的独立预测因子。
  • 上述4个基因在55例原发肿瘤独立队列中经定量实时聚合酶链反应验证。
  • 作者认为这些标志物未来可能用于个体化风险适配治疗。

核心结论

  • TOP2A、HELLS、ATAD2和TET3的高mRNA水平是肾细胞癌患者不良结局的独立预测因子,未来可能用于个体化风险适配治疗。

研究设计与样本

  • 从肾细胞癌患者的正常肾组织、原发G1和G3肿瘤(各14例)及32例转移灶中分离总RNA,用寡核苷酸微阵列建立表达谱。
  • 在55例原发肿瘤独立队列中用定量实时聚合酶链反应验证最佳候选标志物的表达。

主要发现

  • 59个基因在原发肾细胞癌中较正常肾表达升高,且在转移灶中较原发肿瘤表达升高。
  • 单因素或多因素生存分析中,15个基因的上调有统计学意义,其中8个基因经定量实时聚合酶链反应验证。
  • 在55例肾细胞癌患者独立队列中,基于原发肿瘤表达,TOP2A(HR=4.3,P=.005)、HELLS(HR=3.7,P=.007)、ATAD2(HR=3.7,P=.019)和TET3(HR=2.8,P=.035)是癌症特异性生存的独立预测因子。

关键数值与推荐

  • 基因表达差异的显著性阈值定为P<.05。
  • TOP2A的HR=4.3(P=.005),HELLS的HR=3.7(P=.007),ATAD2的HR=3.7(P=.019),TET3的HR=2.8(P=.035),均为癌症特异性生存的独立预测因子。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify and validate novel prognostic marker genes in clear cell renal cell carcinoma (RCC) that are increasingly expressed during tumor progression. METHODS: Total RNA was isolated from normal renal tissue, primary G1 and G3 tumors, 14 samples each, and 32 metastases from RCC patients. Expression profiles were created using oligonucleotide microarrays. Significant gene expression differences (P < .05) were identified among normal kidney, primary tumor, and metastases. For all filtered genes, univariate survival analysis was carried out. Genes for which lower expression was significantly associated with longer survival were further analyzed using multivariate analysis. Expression of the best candidate markers was further validated in an independent cohort of 55 primary tumors using quantitative real-time polymerase chain reaction. RESULTS: Fifty-nine genes exhibited increased expression in primary RCC compared with normal kidney, and in metastases compared with primary tumors. In univariate or multivariate survival analysis, upregulation of 15 genes was significant. Expression of 8 genes was validated by quantitative real-time polymerase chain reaction. Survival analysis in an independent cohort of 55 RCC patients based on expression in primary RCC showed that TOP2A (hazard ratio [HR] = 4.3, P = .005), HELLS (HR = 3.7, P = .007), ATAD2 (HR = 3.7, P = .019), and TET3 (HR = 2.8, P = .035) represent independent predictors for cancer-specific survival. The proteins encoded by these genes function as topoisomerase, helicase, chromatin modifier, and methyl cytosine dioxygenase, respectively. They are involved in proliferation, transcription, and epigenetic modification. CONCLUSION: High mRNA levels of TOP2A, HELLS, ATAD2, and TET3 are independent predictors of poor outcome in RCC patients and may be used for individual risk-adapted therapy in the future.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chen D, Maruschke M, Hakenberg O, et al. TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma. Urology. 2017. PMID: 28069330. doi:10.1016/j.urology.2016.12.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。